Central Pressor Actions of Aminopeptidase-resistant Angiotensin II Analogs: Challenging the Angiotensin III Hypothesis
Overview
Authors
Affiliations
Unlabelled: Intracerebroventricular administration of angiotensins causes pronounced pressor and dipsogenic responses. The suggestion that angiotensin III rather than angiotensin II is the active peptide in the brain spawned what we call The Angiotensin III.
Hypothesis: To test this hypothesis, 5 angiotensin II analogs containing zero or one position substitutions conferring resistance to aminopeptidases were administered intracerebroventricularly to determine their pressor and dipsogenic efficacies. Two aminopeptidase-resistant analogs caused significantly greater pressor responses than angiotensin II, whereas 3 analogs caused pressor responses similar to angiotensin II. Latency to cause a pressor response for 4 of the 5 aminopeptidase-resistant angiotensin II analogs was the same as for angiotensin II. There was no detectable formation of (125)I-angiotensin III from 1 of the intracerebroventricularly administered analogs, (125)I- N-Methyl-l-Asp(1)-angiotensin II, indicating its aminopeptidase resistance. Latency to drink also did not differ between the angiotensins. After the initial dipsogenic response, water was removed until 25 minutes after angiotensin administration to avoid interfering with the pressor response. The dipsogenic stimulus was sustained 25 minutes after intracerebroventricular injection of angiotensin II and its aminopeptidase-resistant analogs. Comparison of angiotensin III and angiotensin II showed equivalent pressor responses with similar latencies and durations. The latency to drink was similar for angiotensin III and angiotensin II. However, there was no dipsogenic response to angiotensin III 25 minutes after intracerebroventricular injection. These data do not support The Angiotensin III Hypothesis and suggest that conversion of exogenously applied angiotensin II to angiotensin III is not necessary to cause brain-mediated pressor or dipsogenic responses.
Current Knowledge about the New Drug Firibastat in Arterial Hypertension.
Hansen E, Grimm D, Wehland M Int J Mol Sci. 2022; 23(3).
PMID: 35163378 PMC: 8836050. DOI: 10.3390/ijms23031459.
Mehranfard D, Perez G, Rodriguez A, Ladna J, Neagra C, Goldstein B J Renin Angiotensin Aldosterone Syst. 2021; 2021:9987115.
PMID: 34285715 PMC: 8277508. DOI: 10.1155/2021/9987115.
Revisiting the Brain Renin-Angiotensin System-Focus on Novel Therapies.
Ren L, Lu X, Danser A Curr Hypertens Rep. 2019; 21(4):28.
PMID: 30949864 PMC: 6449495. DOI: 10.1007/s11906-019-0937-8.
Miller A, Arnold A Clin Auton Res. 2018; 29(2):231-243.
PMID: 30413906 PMC: 6461499. DOI: 10.1007/s10286-018-0572-5.
Distinct Molecular Effects of Angiotensin II and Angiotensin III in Rat Astrocytes.
Clark M, Nguyen C, Tran H Int J Hypertens. 2013; 2013:782861.
PMID: 23476748 PMC: 3586509. DOI: 10.1155/2013/782861.